Ticker brief
URGN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
6
crowd 14d
+0.2σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-26 · now +0.25 (−1 bearish … +1 bullish)
Who spoke6
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @BioStocks | C | -3.02 | 1 | +0.25 |
| @VladBastion | B | -1.80 | 1 | +0.40 |
| @AponiaAnalytics | B | +4.91 | 1 | +0.45 |
| @BiopharmIQ | B | · | 1 | +0.10 |
| @CEOStockWatcher | C | · | 1 | -0.20 |
| @TheNewMoney_app | C | · | 1 | +0.25 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-26 | @TheNewMoney_app | +0.25 | Reports 114,240 dollars of URGN 60 calls purchased for November 2026. | · | tweet ↗ |
| 2026-08-25 | @CEOStockWatcher | -0.20 | UroGen's Chief Medical Officer made their largest disclosed sale. | · | tweet ↗ |
| 2026-08-20 | @BiopharmIQ | +0.10 | Biotech movers are linked to FDA feedback, clinical data and partnership developments across four named companies. | · | tweet ↗ |
| 2026-08-17 | @AponiaAnalytics | +0.45 | Views UGN-103 as a lifecycle opportunity that could extend the franchise if approved. | · | tweet ↗ |
| 2026-08-17 | @VladBastion | +0.40 | Presents five highly rated pharma growth stocks as a thematic basket. | · | tweet ↗ |
| 2026-08-17 | @BioStocks | +0.25 | UroGen submitted an NDA for UGN-103 in recurrent LG-IR-NMIBC. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.